Subsequently, we established a coculture system of activated CD8+ T cells and GBM cells, and the western blotting and flow cytometry results showed that anti-VEGFR2 therapy promotes the toxic effect of immune cells on GBM cells. This evidence concerns the gene CD8A and glioblastoma.